Nucleome Therapeutics

Nucleome is an immunology company tackling the root causes of disease through a revolutionary new approach to solving human genetics. Nucleome has a deep molecular understanding of the function and importance of the non-coding genome and how variation within it causes disease. The Company has created transformative 3D genomics technology to link disease-associated genetic variants with the genes they dysregulate in disease. At the core of this, is the ability to read 3D interactions in the non-coding genome with a precision and scale that is unique in both industry and academia.

Nucleome is the first company to build at scale a rich data atlas of immune system dysregulation identified from human disease genetics, allowing it to elucidate the mechanistic basis of disease, identify hundreds of novel targets and group patients by their common, mechanistic disease drivers. The Company is building a pipeline of genetically identified therapeutics to restore health in inflammatory diseases, with lead programme, NTP464, in pre-clinical development.

Nucleome is backed by a world-class syndicate of investors: M Ventures, the venture capital arm of Merck KGaA; Johnson and Johnson Innovation - JJDC, Inc. (“JJDC”); Pfizer Ventures; British Business Bank and founding investor Oxford Science Enterprises. Visit the website to find out more at: www.nucleome.com

• Immunology/inflammation
• Genetics/Genomics
• Platform Technology
• Autoimmune diseases